![Design of new quinolin-2-one-pyrimidine hybrids as sphingosine kinases inhibitors. - Abstract - Europe PMC Design of new quinolin-2-one-pyrimidine hybrids as sphingosine kinases inhibitors. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6954317/bin/nihms-1065234-f0009.jpg)
Design of new quinolin-2-one-pyrimidine hybrids as sphingosine kinases inhibitors. - Abstract - Europe PMC
![Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML | Leukemia Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML | Leukemia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fleu.2017.9/MediaObjects/41375_2017_Article_BFleu20179_Fig2_HTML.jpg)
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML | Leukemia
![Design of new quinolin-2-one-pyrimidine hybrids as sphingosine kinases inhibitors. - Abstract - Europe PMC Design of new quinolin-2-one-pyrimidine hybrids as sphingosine kinases inhibitors. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6954317/bin/nihms-1065234-f0008.jpg)